CNTA vs. RDY, ASND, VTRS, ROIV, QGEN, ELAN, BBIO, MRNA, VRNA, and RVMD
Should you be buying Centessa Pharmaceuticals stock or one of its competitors? The main competitors of Centessa Pharmaceuticals include Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Roivant Sciences (ROIV), Qiagen (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.
Centessa Pharmaceuticals vs. Its Competitors
Centessa Pharmaceuticals (NASDAQ:CNTA) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.
Dr. Reddy's Laboratories has a net margin of 16.99% compared to Centessa Pharmaceuticals' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 17.25% beat Centessa Pharmaceuticals' return on equity.
Centessa Pharmaceuticals currently has a consensus target price of $32.38, indicating a potential upside of 40.76%. Dr. Reddy's Laboratories has a consensus target price of $16.95, indicating a potential upside of 20.04%. Given Centessa Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Centessa Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.
Dr. Reddy's Laboratories has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.
In the previous week, Centessa Pharmaceuticals had 6 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 7 mentions for Centessa Pharmaceuticals and 1 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.89 beat Centessa Pharmaceuticals' score of 0.68 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.
Centessa Pharmaceuticals has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.
82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 7.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Centessa Pharmaceuticals and Dr. Reddy's Laboratories tied by winning 8 of the 16 factors compared between the two stocks.
Get Centessa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Centessa Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CNTA) was last updated on 10/6/2025 by MarketBeat.com Staff
